When Therapies Don't Reach Patients

A clinically proven, AI-enabled therapy addressing a major unmet medical need is ready for deployment, yet its path to patients remains uncertain. Pricing, reimbursement, and regulatory frameworks continue to challenge the translation of biomedical innovation into clinical practice. As US policy reshapes global incentives and China strengthens its biotech ecosystem, Europe faces growing pressure to maintain its leadership in turning scientific breakthroughs into patient benefit.